Program
Please Note: All session times for the AACR Special Conference: Ovarian Cancer are U.S. Eastern Time (ET).
Tuesday, September 14
Plenary Session 1: Epidemiology and Cancer Prevention
10-11:40 a.m.
Session Chair: Elizabeth M. Swisher, University of Washington, Seattle, Washington
Opportunistic salpingectomy: One decade later
Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada
Ovarian cancer detection and risk assessment using high fidelity sequencing
Rosana Risques, University of Washington, Seattle, Washington
PALB2, ovarian cancer gene?
Barbara Norquist, University of Washington, Seattle, Washington
Endometriosis and ovarian cancer risk
Holly Harris, Fred Hutchinson Cancer Center, Seattle, Washington
Panel Discussion
Break
11:40-11:55 a.m.
Plenary Session 2: Ovarian Cancer Genetics, Epigenetics, and Evolution
11:55 a.m.-1:35 p.m.
Session Chair: Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, New York
Longitudinal, multi-region assessment of tumor evolution in patients with high-grade serous ovarian cancer
Sampsa Hautaniemi, University of Helsinki, Helsinki, Finland
Rewiring of transcriptional circuits during high-grade serous ovarian cancer development
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, California
Genomic and immunological features of high-grade serous ovarian cancer in long-term survivors
Dale W. Garsed, Peter MacCallum Cancer Centre, Melbourne, Australia
Panel Discussion
Wednesday, September 15
Plenary Session 3: DNA Damage and Replication Stress
10-11:40 a.m.
Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Overcoming PARP inhibitor resistance
Alan D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
USP1-trapping lesions as a source of DNA replication stress and genomic instability
Tony Huang, NYU Langone Health Perlmutter Cancer Center, New York, New York
The role of BRCA1 mutations in promoting therapy resistance
Neil Johnson, Fox Chase Cancer Center, Philadelphia, Pennsylvania
The success and challenges of introducing PARP inhibitors into the therapy of ovarian cancer
Jonathan A. Ledermann, UCL Cancer Institute at University College London, London, United Kingdom
Panel Discussion
Break
11:40-11:55 a.m.
Plenary Session 4: Immunology and Tumor Microenvironment
11:55 a.m.-1:35 p.m.
Session Chair: Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England
Single-cell spatial proteomic profiling of the tumor microenviroment for biomarker discovery in ovarian cancer
Anniina Färkkilä, University of Helsinki, Helsinki, Finland
Engineering adoptive T cell therapy to overcome immune suppression in ovarian cancer
Kristin G. Anderson, Fred Hutchinson Cancer Center, Seattle, Washington
Mechanisms of tumor immunogenicity and anti-tumor immunity in ovarian cancer
Denarda Dangaj, Ludwig Institute for Cancer Research UNIL CHUV, Lausanne, Switzerland
Mutational processes as determinants of immunophenotypes in ovarian cancer
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York
Panel Discussion